

SUB
B11

- [illegible]

pharmaceutical composition as compared to the undenatured composition.

5. The pharmaceutical composition according to claim 1 wherein said sympathomimetic amine is selected from the group consisting of pseudoephedrine hydrochloride, pseudoephedrine sulfate, ephedrine hydrochloride and phenylpropanolamine hydrochloride.

6. The pharmaceutical composition according to claim 5 wherein said sympathomimetic amine is pseudoephedrine hydrochloride.

7. The pharmaceutical composition according to claim 1 wherein said other pharmacologically active compound is selected from the group consisting of methamphetamine, amphetamine, methacathinone and cathinone.

8. The pharmaceutical composition according to claim 7 wherein said other pharmacologically active compound is methamphetamine.

9. The pharmaceutical composition according to claim 1 wherein said combination inhibitor is selected from the group consisting of transition metal salts and amino polymers.

10. The pharmaceutical composition according to claim 9 wherein said amino polymer is in a neutralized salt form.

11. The pharmaceutical composition according to claim 10 wherein said amino polymer is from about 1% to about 100% in the neutralized salt form.

FOUO 11-22-96

12. The pharmaceutical composition according to claim 10 wherein said amino polymer is from about 50% to about 100% in the neutralized salt form.

13. The pharmaceutical composition according to claim 10 wherein said amino polymer is from about 70% to about 100% in the neutralized salt form.

14. The pharmaceutical composition according to claim 10 wherein said amino polymer is from about 85% to about 98% in the neutralized salt form.

15. The pharmaceutical composition according to claim 9 wherein said amino polymer is a copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.

16. The pharmaceutical composition according to claim 15 wherein said amino polymer is the neutralized hydrochloride salt form of the copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.

17. The pharmaceutical composition according to claim 16 wherein said copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate is from about 1% to about 100% in the neutralized hydrochloride salt form.

18. The pharmaceutical composition according to claim 16 wherein said copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate is from about 50% to about 100% in the neutralized hydrochloride salt form.

19. The pharmaceutical composition according to claim 16 wherein said copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate is

20. The pharmaceutical composition according to claim 16 wherein said copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate is from about 85% to about 98% in the neutralized hydrochloride salt form.

21. The pharmaceutical composition according to claim 15 wherein said copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate is homogeneously mixed together with said sympathomimetic amine and all other components of said pharmaceutical composition.

22. The pharmaceutical composition according to claim 15 wherein said copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate coats said sympathomimetic amine prior to mixing with all other components of said pharmaceutical composition.

23. The transition metal salt according to claim 9 wherein said transition metal is selected from the group consisting of iron, cobalt, copper, chromium, manganese, nickel and zinc.

24. The transition metal salt according to claim 9 wherein the anion of said transition metal salt is selected from the group consisting of chloride, oxide, sulfate and gluconate.

25. The pharmaceutical composition according to claim 9 wherein said transition metal salt is selected from the group consisting of ferric chloride, ferric oxide, ferrous sulfate, ferrous chloride, ferrous gluconate ferrous oxide, zinc gluconate and copper gluconate.

26. The pharmaceutical composition according to claim 25 wherein said transition metal salt is selected from the group consisting of ferrous gluconate, zinc gluconate and copper gluconate.

27. The pharmaceutical composition according to claims 2 or 4 wherein said reaction inhibitor is selected from the group consisting of water insoluble polyhydroxy compounds, non-polymeric water soluble polyhydroxy compounds and solvent soluble ester compounds.

28. The pharmaceutical composition according to claim 27 wherein said water insoluble polyhydroxy compound is selected from the group consisting of ethylcellulose and cellulose.

29. The pharmaceutical composition according to claim 27 wherein said non-polymeric water soluble polyhydroxy compound is selected from the group consisting of glycerin, sorbitol, lactitol, mannitol, xylitol, maltitol and galactose.

30. The pharmaceutical composition according to claim 27 wherein said solvent soluble ester is selected from the group consisting of glycerin esters, esters of glycerin polymers, sorbitol esters, propylene glycol esters, polyethylene glycol esters, sucrose esters and esters of ethoxylated fatty alcohols.

31. The pharmaceutical composition according to claims 3 or 4 wherein said separation inhibitor is selected from the group consisting of water soluble cellulose compounds, polysaccharide gums, polyethylene oxide polymers, acrylic acid polymers, starches, magnesium aluminum silicates, polyvinylpyrrolidones and clays.

Add
B27